GLP-1 Weight Loss Calculator

How Does This GLP-1 Calculator Work?

This calculator uses published clinical trial data to predict your potential weight loss on three GLP-1 medications: Tirzepatide (Zepbound), Semaglutide injection (Wegovy), and oral Semaglutide. It factors in your current weight, height, age, gender, and diabetes status to provide a personalized prediction.

What Affects GLP-1 Weight Loss Results?

The biggest factor is which medication you take - Tirzepatide shows higher average weight loss (21%) compared to Semaglutide injection (15%). Diabetes status significantly impacts results: patients with higher A1C levels tend to lose less weight, with reductions of 20–40% from the baseline prediction.

Factors That Impact Weight Loss on GLP-1 Medications

Two people can take the same GLP-1 medication at the same dose and have completely different results. One loses 60 pounds in a year. The other barely moves the scale. This is one of the most common frustrations I hear from patients, and it deserves a thorough explanation. The calculator above gives you a data-driven estimate, but the reality is that your results depend on a complex mix of factors - many of which are within your control, and some that are not.

The Medications: Not All GLP-1s Are Created Equal

The specific medication you take is one of the biggest determinants of how much weight you will lose. Not all GLP-1 medications work the same way or produce the same outcomes.

Zepbound (tirzepatide) is a dual GIP/GLP-1 receptor agonist, meaning it targets two hormonal pathways instead of one. In clinical trials, patients on Zepbound lost an average of approximately 21% of their body weight - substantially more than any other medication in this class. For someone weighing 250 pounds, that translates to roughly 52 pounds.

Wegovy (semaglutide injection) targets only the GLP-1 receptor and produces an average weight loss of approximately 15–16% of body weight. That is still remarkable - far more effective than any previous weight loss medication - but the gap between Wegovy and Zepbound is clinically meaningful.

Rybelsus (oral semaglutide) is a pill form of semaglutide. While convenient, it is generally less potent than injectable semaglutide because oral absorption is less efficient. Patients switching from Rybelsus to an injectable option should work closely with their physician, and Zepbound is often recommended over injectable Wegovy when making that transition due to its dual mechanism and stronger clinical results.

Diabetic vs. Non-Diabetic Patients

One of the most consistent findings across clinical trials is that patients with type 2 diabetes lose less weight on GLP-1 medications than non-diabetic patients. This is not about effort or willpower - it is biology.

On Zepbound, non-diabetic patients average about 21% body weight loss, while diabetic patients average closer to 15%. On Wegovy and Ozempic (both semaglutide), the difference is similarly stark: non-diabetic patients lose approximately 15–16%, while diabetic patients average around 9%. The higher your A1C, the greater this reduction tends to be.

Why does this happen? Insulin resistance changes how your body responds to these medications. The hormonal signaling that GLP-1 drugs enhance is already dysregulated in diabetic patients, which blunts the appetite-suppressing and metabolic effects. This does not mean GLP-1 medications are not worth taking if you have diabetes - they absolutely are, and the weight loss is still clinically significant. It just means your expectations should be calibrated differently.

Individual Response: Why Averages Do Not Tell the Whole Story

Clinical trial averages are useful, but they mask enormous individual variation. The average patient on a GLP-1 medication loses roughly 30–40 pounds. But that average includes people who lost 80 pounds and people who lost 10.

Approximately 15% of patients are considered non-responders - they lose minimal weight despite taking the medication as directed. Emerging research suggests this may be related to genetic factors, gut microbiome composition, and individual differences in hormonal signaling. If you are in this group, it does not mean you have failed. It means the medication is not the right tool for your biology, and you should discuss alternatives with your care team, including surgical weight loss options.

On the other end of the spectrum, emerging research shows that combining lifestyle changes with medication dramatically amplifies outcomes. In one study, patients who lost approximately 7% of their body weight through diet alone and then added Zepbound went on to lose an additional 26% - far exceeding what either approach achieved independently. This underscores what we emphasize at our practice: lifestyle and medication work best together, not as substitutes for each other.

Other Factors That Influence Your Results

• Starting weight: Patients with a higher starting BMI often lose more total weight, though the percentage loss can be similar across weight ranges.
• Dose and titration: GLP-1 medications are titrated gradually. Reaching the maximum effective dose takes weeks to months. Patients who tolerate higher doses tend to see better results.
• Side effect tolerance: Nausea, vomiting, and GI side effects are common, especially early on. If side effects force you to stay on a lower dose or stop the medication altogether, your results will be limited.
• Diet and lifestyle: Diet quality matters significantly. Patients who focus on whole foods, adequate protein, and consistent meal patterns tend to lose more weight and maintain it longer. Tools like the Loli AI weight loss app can help with daily tracking and accountability.
• Insurance and cost: GLP-1 medications are expensive without insurance coverage. Gaps in access - whether from prior authorization delays, formulary restrictions, or out-of-pocket costs - can disrupt treatment and reduce outcomes.
• Duration of treatment: Weight loss on GLP-1 medications continues to accumulate over 12–18 months. Stopping the medication prematurely is one of the most common reasons patients do not reach their projected weight loss.

Setting Realistic Expectations

Comparison is the enemy of progress when it comes to GLP-1 weight loss. The variance between patients is enormous, and social media is filled with cherry-picked success stories that do not represent the typical experience. Your coworker who lost 70 pounds on Wegovy might have a very different metabolic profile, starting point, and set of circumstances than you do.

The right benchmark is your own progress, not someone else's. Work with your care team to set a realistic target based on your specific medication, health status, and starting point. Use our bariatric surgery calculator to compare projected outcomes if you are also considering surgical options.

What matters most is sustainable, medically meaningful weight loss - even a 10% reduction in body weight significantly improves blood pressure, blood sugar, cholesterol, sleep apnea, joint pain, and overall quality of life. Whether you lose 15% or 25%, you are making a profound investment in your long-term health.

The Bottom Line

GLP-1 medications are the most effective non-surgical weight loss tools ever developed, but they are not one-size-fits-all. Your results will depend on which medication you take, whether you have diabetes, how your body individually responds, the lifestyle changes you make alongside the medication, and how long you stay on treatment. The calculator above gives you a data-driven starting point. For a personalized plan that accounts for all of these factors, learn more about our GLP-1 medication programs or explore our full non-surgical weight loss approach.